<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27328670</article-id><article-id pub-id-type="pmc">4916533</article-id><article-id pub-id-type="publisher-id">2403</article-id><article-id pub-id-type="doi">10.1186/s12885-016-2403-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Bridgewater</surname><given-names>John</given-names></name><address><email>j.bridgewater@ucl.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Lopes</surname><given-names>Andre</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Beare</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Duggan</surname><given-names>Marian</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Dymphna</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Ricamara</surname><given-names>Maravic</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>McEntee</surname><given-names>Delyth</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Sukumaran</surname><given-names>Ajithkumar</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Wasan</surname><given-names>Harpreet</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Valle</surname><given-names>Juan W.</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff1"><label/>UCL Cancer Institute, 72 Huntley St, London, WC1E 6DD UK </aff><aff id="Aff2"><label/>Cancer Research UK and UCL Clinical Trials Centre, London, UK </aff><aff id="Aff3"><label/>The Christie NHS Foundation Trust, Manchester, UK </aff><aff id="Aff4"><label/>Imperial College Healthcare, London, UK </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>16</volume><elocation-id>369</elocation-id><history><date date-type="received"><day>15</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>15</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><related-article related-article-type="corrected-article" id="d30e75" ext-link-type="doi" xlink:href="10.1186/s12885-016-2174-8"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum</title><p>After publication of the original article [<xref ref-type="bibr" rid="CR1">1</xref>], the authors noticed an error in the Acknowledgements section. The Acknowledgement contains missing information. The correct version of the Acknowledgements section is included below:</p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1186/s12885-016-2174-8.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The research was funded in part by AstraZeneca and carried out at, and supported by, the National Institute for Health Research (NIHR UCLH Clinical Research Facility and the Cancer Research UK Experimental Cancer Medicine Centre (ECMC). Central coordination of the study was supported by Cancer Research UK (Grant reference C1813/A12155) and AstraZeneca. Conduct of the trial at hospital sites was supported through the National Institute of Health Research Clinical Research Network and AstraZeneca. We also acknowledge the support of the AMMF (<ext-link ext-link-type="uri" xlink:href="http://www.ammf.org.uk/">www.ammf.org.uk/</ext-link>) and the IBTCC (International Biliary Tract Cancer Collaboration). JB is partly funded by the UCLH/UCL NIHR Biomedical Research Centre.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bridgewater</surname><given-names>J</given-names></name><name><surname>Lopes</surname><given-names>A</given-names></name><name><surname>Beare</surname><given-names>S</given-names></name><name><surname>Duggan</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Ricamara</surname><given-names>M</given-names></name><etal/></person-group><article-title>A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study</article-title><source>BMC Cancer</source><year>2016</year><volume>16</volume><fpage>153</fpage><pub-id pub-id-type="doi">10.1186/s12885-016-2174-8</pub-id><pub-id pub-id-type="pmid">26912134</pub-id></element-citation></ref></ref-list></back></article>